Trial Profile
A Randomized Phase II Study of Induction Chemotherapy Followed by Concurrent Chemoradiation Therapy According to EGFR Mutation Status in Patients With Unresectable Stage III NSCLC.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Irinotecan
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Oct 2010 Planned end date changed from Mar 2011 to Mar 2015 as reported by ClinicalTrials.gov.
- 26 Mar 2008 New trial record.